Cortexyme announces q2 2020 financial results and provides business update

Cortexyme announces second quarter 2020 financial results and provides business update.q2 loss per share $0.60.q2 earnings per share estimate $-0.62 -- refinitiv ibes data.gain trial interim analysis on schedule to complete by year end 2020.clinical pipeline expansion anticipated in 2021.cortexyme - expects current cash, cash equivalents & marketable securities will be sufficient to fund operating & capital expenditures through 2022.
QNCX Ratings Summary
QNCX Quant Ranking